$CLVT

Snyder Andrew Miles sold $4.8M of CLVT (indirect holdings)

Snyder Andrew Miles sold 2,489,618 indirectly-held shares of CLARIVATE PLC (CLVT) at $1.94 ($4.83M total) across 3 trades on 2026-08-03.

Original reporting
SEC EDGAR · Snyder Andrew Miles
Published Aug 5, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 6:29 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CLVT
Neutral
medium confidence
Mentioned
$CLVT
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLVTNeutralLow
01

Why it matters

The newest fact is the director’s open-market sale details (shares, price, total value) and that it was not under a pre-arranged 10b5-1 plan.

02

Market read

Traders may monitor for follow-on insider activity or broader sentiment, but there is no new operational or financial guidance in the text.

03

What to watch

The article does not state total compensation, tax obligations, or whether other insiders sold/bought around the same time, limiting inference from a single transaction.

Relevance 6/10Novelty 5/10Timing: SEC Form 4 filed Aug 5, covering Aug 3 sales.

Background

The article is an SEC Form 4 insider transaction disclosure for Clarivate PLC (CLVT).

Company-level read

Ticker impact

$CLVTNeutralMedium confidence
Context

Clarivate PLC director Snyder Andrew Miles sold 2,489,618 shares in open-market transactions at $1.94/share, per a new SEC Form 4 filed Aug 5.

Expected impact

Low likelihood of a sustained price move; any reaction is likely limited to short-term sentiment around insider selling.

Evidence & confidence

The filing discloses transaction size and price, but provides no new guidance, deal, or operational change. Also, the filing states no pre-arranged 10b5-1 plan, which can increase interpretive sensitivity, though it still does not establish a new company-specific catalyst.

Market effects

Minimal. Insider selling in a single name does not materially reset sector fundamentals.

Minimal, as the disclosure is company-specific and not a macro/regional policy event.

Minimal, no cross-border deal, regulation, or supply-chain shock described.

Counterpoint

The absence of a 10b5-1 plan can be misread as bearish; the sale could be routine liquidity or tax-related, so the market reaction may overstate signal.

Key entities

  • Clarivate PLC

    Subject of the Form 4 insider transaction disclosure (CLVT).

  • Snyder Andrew Miles

    Director who sold shares via open-market transactions; filing reports indirect holdings and post-transaction share count.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CLVTMed

Clarivate Completes Sale of Life Sciences & Healthcare Segment, Advances Strategic Transformation

Clarivate (NYSE: CLVT) completed the $600M sale of its Life Sciences & Healthcare segment to Altaris, simplifying its portfolio and focusing on Academia & Government and Intellectual Property segments. The company plans to use proceeds to reduce debt and strengthen its balance sheet, aiming to drive growth and shareholder value. Clarivate will update its full-year 2026 guidance on November 3, 2026.